Huidu Medical completed a billion-dollar B-1 round of strategic financing, focusing on clinical trials of new drugs and early screening of cancer.

Guide: Strategic financing, focusing on new drug research and development, but also the best way to integrate resources.
, July 29, 2020, Huidu Medical recently announced the completion of more than RMB 100 million of B-1 round of strategic financing.
this investment is led by Kangjun Capital, existing shareholders Hirohito Capital and Xianxian Capital.
this round of financing will be used mainly for global market business development, team building and product development.
Huidu Medical was established in 2015 to successfully develop a new generation of liquid biopsy technology and algorithmic models based on the highly hypersensitive RNA-DNA "gene radar" with the efforts of an elite team from industry and academia, and to build a closed-loop gene detection system and intelligent medical data platform based on blood, urine and tumor tissue.
Huidu Medical, which has both CLIA and CAP International StandardS Laboratories in Shanghai and Silicon Valley, provides a global, one-stop and comprehensive solution for global, one-stop and all-round biomarker precision diagnostics, bioinformatics and medical big data for clinical trials for domestic and international pharmaceutical customers, including seven of the world's top 10 pharmaceutical companies.
Huidu Medical also maintains in-depth cooperation with internationally renowned clinical hospitals and academic institutions, and has published several influential academic articles in the field of liquid biopsy in internationally renowned professional journals such as EuropeanUrology, EBioMedicine, BreastCancer Research, etc.
facing the need for clinical, Huidu Medical through genetic radar technology and TMB and other 5 liquid biopsy products in the new drug clinical trials, personalized medicine and early cancer screening three areas of the layout of the tumor of the full precision management, and through the establishment of intelligent medicine big data platform to empower precision medicine.
talking about future development plans, Saidi Jia, founder, chairman and CEO of Huidu Medical, said, "I am particularly grateful for the trust and support of new and existing shareholders."
the introduction of Kangjun Capital as an industrial strategic investor, is Huidu medical business model and development direction of full affirmation! After this round of financing, we will realize the service and product two-wheel drive, adhere to the patient-centered, scientific and technological innovation-driven principle, through the formation and improvement of intelligent medicine big data platform to further vertical deep-cultivation of global clinical trials of new drugs, tumor recurrence monitoring and early cancer screening field, committed to the early completion of a full range of precision medical strategy layout! Mr. Lou Xiaoqiang, Chairman of Kangjun Capital, said, "We are very honored to participate in Huidu Medical's precision medicine business!" With the increasing popularity of personalized precision medicine in the development of new cancer drugs, the role of biomarker precision diagnosis, bioinformatics and medical big data in clinical trials of new drugs is becoming more and more important.
Huidu Medical has established cooperative relations with well-known pharmaceutical companies at home and abroad, and the technology platform and service quality have been recognized by customers.
hopes that Huidu Medical will help more clinical trials of new drugs and provide patients with more accurate and effective innovative drugs and treatment options.
"About Kangjun Capital (Bayland Capital) is a professional investment institution in the field of biomedicine co-sponsored by Kanglonghua As a joint junlian capital, focusing on biopharmaceutical research and development services and technology innovation platforms worldwide.
Kanglong into a (stock code: 300759. SZ/3759.HK) is the world's leading life sciences research and development services enterprises, in China, the United States, the United Kingdom have operating entities, with more than 8,000 employees, first-class talent, high-quality research and development services, has been widely recognized by the industry, with North America, Europe, Japan and China's pharmaceutical companies/ institutions to maintain long-term, solid relations of cooperation.
Kangjun Capital fully rely on Kanglong into a strong new drug research and development service platform and Junlian capital mature investment system, through the global industrial perspective, insight into the industry's cutting-edge technology and excellent enterprises;
, HLC is a company focused on investing in "healthy living" and serving a leading company that provides scientific and technological products and differentiated services for the diagnosis and treatment of human life and healthy living, with in-depth research and practice in the fields of bioengineering, medical devices, diagnostic equipment, personal care and health care.
manages dual-currency funds in both RMB and USD, with a combined capital of more than RMB10 billion.
has invested in high-quality projects such as: Meirui Medical, Kang Longhua, Pharmaceutical Mingkang, Pharmaceutical Sinbet, Fish Leap Medical, Boray Pharmaceuticals, Pioneering Pharmaceuticals, Sanxiang Bio, United Shadow Medical, ZENTALIS, MALO, BEABA, Seymour, Andelu's Tea.
about Xianxian Capital Xianxian Capital is one of the first professional biomedical equity investment institutions in China, focusing on biomedicine, medical devices, biotechnology, in the bio-medical investment industry has leading professional advantages and rich project reserves.
based on the most promising industries, Xianxian Capital taps innovative growth enterprises with great capital value and commercial potential, and cultivates a number of sub-industry benchmarks. with offices in Shenzhen, Beijing, Suzhou and the United States,
Xianxian Capital brings together several investment and advisory teams of industry experts, scientists and investors in the field of life science and technology, manages and operates a series of RMB and US dollar funds, and has been awarded honorary awards by several institutions.
.